NOTES: Abbott: Abbott's Electronic Apothecary is a Flesh Trap
The dark reality of the electronic apothecary. When chronic pain management becomes a proprietary biological lease, patients are trapped by catastrophic battery drains, mandatory surgical revisions, and dangerous MRI bottlenecks.
Listen on
Listen (episode)SpotifyApple PodcastsRSS
The Cassandra Files — forensic audio drama. Katie audits the books, Marcus kills the spin, Killian opens the file. About · Latest · Themes
I haven't felt a chill like this since a neon-soaked bender in Shinjuku back in 2018, staring at a proprietary digital menu I couldn't navigate while my wallet slowly bled out. That same creeping realization—that you are trapped in a closed-loop ecosystem designed exclusively to fleece you—is exactly what I see in Abbott's latest clinical ledger. Welcome to the era of the "Electronic Apothecary."
The official pitch from device manufacturers is undeniably seductive. With institutional capital fleeing the liabilities of chemical painkillers, Abbott’s Proclaim system offers a structural pivot. By targeting the Dorsal Root Ganglion (DRG), this implant intercepts localized pain signals before they ever reach the central nervous system. They are selling a definitive victory over the chronic care treadmill. Just wire the hardware into your spine, bypass the pharmacology, and enjoy the durable relief.
But the physiological reality is a masterclass in captive recurring revenue.
Interfacing hardware with the human nervous system introduces a brutal engineering deficiency. The physical resistance—the impedance—at the DRG is remarkably high. To maintain therapeutic thresholds, the Proclaim system chews through its internal power supply at a catastrophic rate. Early placebo-controlled trials conveniently focused on short-term pain reduction ROI, effectively obscuring this rapid hardware decay.
When the power inevitably dies, you don't just plug into a wall. You undergo a mandatory surgical revision. Abbott spins this as a calculated clinical trade-off: a scheduled outpatient procedure in exchange for pain relief. From where I sit, it is a biological lease. You aren't cured; your anatomy has simply been converted into a host for proprietary hardware maintenance. They hold the master key, and the toll is paid in scalpel strokes.
Then comes the diagnostic bottleneck. If you need a routine MRI to figure out why your spine is still screaming, the implant becomes a potentially life-threatening liability. On January 23rd of this year, Abbott secured FDA approval for prone MRI scans in 1.5 Tesla machines. But to avoid severe thermal tissue damage, patients must lie face-down in massive-bore scanners that half the regional hospitals do not even own. It is conditionally safe in the same way a Fitzroy landlord returning your bond is technically a right. It is a legal ghost, an infrastructural fix locked behind a VIP tier nobody can actually access.
The bottom line is a bleak portrait of cultural rot. Exiting the chemical pain cycle doesn't free the patient; it merely transfers their dependency to a closed-loop hardware trap. Abbott has built a high-tech vending machine directly into the human spine, and it demands a surgeon's coin just to keep the lights on. The ledger always gets paid, and the market is collecting in flesh.
